Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scinai Immunotherapeutics Ltd.

2.51
+0.09353.86%
Post-market: 2.510.00000.00%17:38 EDT
Volume:1.20K
Turnover:3.07K
Market Cap:2.35M
PE:0.31
High:2.69
Open:2.69
Low:2.51
Close:2.42
Loading ...

Scinai Immunotherapeutics Signs Option Deal to Acquire Italy's Pincell

MT Newswires Live
·
27 Mar

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

PR Newswire
·
27 Mar

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

TIPRANKS
·
05 Mar

Press Release: SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Dow Jones
·
05 Mar

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

PR Newswire
·
06 Jan

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

PR Newswire
·
16 Dec 2024

Press Release: Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dow Jones
·
05 Dec 2024

There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability

Simply Wall St.
·
29 Nov 2024

Press Release: Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dow Jones
·
27 Nov 2024

Scinai Immunotherapeutics Reports Financial Turnaround and Growth

TIPRANKS
·
25 Nov 2024

Scinai Immunotherapeutics Gains Shareholder Confidence

TIPRANKS
·
22 Nov 2024

Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Benzinga
·
22 Nov 2024

Press Release: Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Dow Jones
·
22 Nov 2024

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

PR Newswire
·
31 Oct 2024